Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,149,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $11.49, for a total transaction of $1,149,000.00. Following the completion of the sale, the chief operating officer now directly owns 595,580 shares in the company, valued at approximately $6,843,214.20. This represents a 14.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Eric Venker also recently made the following trade(s):

• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.65, for a total value of $1,165,000.00.

Roivant Sciences Stock Down 1.7 %

NASDAQ:ROIV opened at $11.80 on Friday. The company has a market capitalization of $8.59 billion, a PE ratio of 2.09 and a beta of 1.25. Roivant Sciences Ltd. has a 52-week low of $9.69 and a 52-week high of $13.06. The stock’s 50 day moving average price is $11.91 and its 200 day moving average price is $11.53.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds have recently modified their holdings of the business. FMR LLC raised its position in Roivant Sciences by 5.6% in the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after purchasing an additional 2,593,910 shares during the last quarter. Rubric Capital Management LP increased its stake in Roivant Sciences by 15.0% in the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after purchasing an additional 3,000,000 shares during the period. State Street Corp raised its holdings in shares of Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after buying an additional 1,118,561 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Roivant Sciences by 23.2% during the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock worth $89,400,000 after buying an additional 1,460,205 shares during the period. Finally, DME Capital Management LP grew its holdings in shares of Roivant Sciences by 14.8% during the second quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock worth $50,852,000 after buying an additional 620,470 shares during the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. Finally, Bank of America raised their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and an average price target of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.